Previous 10 | Next 10 |
2024-03-01 00:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-02-29 06:31:00 ET Just one day after the ascendant biotech CRISPR Therapeutics (NASDAQ: CRSP) reported its fourth-quarter earnings on Feb. 21, Chardan Capital analyst Geulah Livshits raised her price target for the stock to $112, suggesting that it could rise by 32% from its cu...
2024-02-26 08:50:00 ET The biotech industry can be risky and volatile, but there are advantages to investing in companies in this field. Many of them develop lifesaving drugs, the kinds we'll need until we can completely eradicate diseases, which doesn't seem likely to happen in the next de...
2024-02-26 06:45:00 ET The hunt for winning biotech stocks never truly ends, and it's easy to see why. Over the last five years, shares of the gene-editing company CRISPR Therapeutics (NASDAQ: CRSP) are up by 146%, easily topping the market's return of 94%. The company recently succ...
2024-02-24 08:30:00 ET Summary CRISPR stock fell nearly 30% in December but has since rebounded, gaining almost 65% through its recent highs. The recent FDA approvals of Crispr's gene-editing therapy have increased the actualization of its growth potential, improving investor sent...
2024-02-21 18:04:03 ET CRISPR Therapeutics AG (CRSP) Citi 2024 Virtual Oncology Leadership Summit Conference February 21, 2024, 01:00 PM ET Company Participants Samarth Kulkarni - Chairman and Chief Executive Officer Conference Call Participants Yigal Nochomo...
2024-02-21 08:48:22 ET More on CRISPR Therapeutics Crispr Therapeutics: Investors Bet Against Casgevy Uptake Biotech And Pharma Diversification Pays Off Vertex And Crispr: Second Casgevy Approval Pushes Revenue Potential Into Multi-Billion Dollar Range Is Cri...
2024-02-21 07:44:28 ET More on CRISPR Therapeutics Crispr Therapeutics: Investors Bet Against Casgevy Uptake Biotech And Pharma Diversification Pays Off Vertex And Crispr: Second Casgevy Approval Pushes Revenue Potential Into Multi-Billion Dollar Range Is Cri...
— CASGEVY™ approved in the U.S., European Union, Great Britain, the Kingdom of Saudi Arabia and Bahrain — — Clinical trials ongoing for next generation CAR T product candidates, CTX112™ and CTX131™ targeting CD...
Kajima Corporation ADR (KAJMY) is expected to report for quarter end 2023-12-31 FaZe Holdings Inc. (FAZE) is expected to report for Q4 2023 BrewBilt MFG Inc (BBRW) is expected to report for Q4 2023 Correlate Energy Corp. (CIPI) is expected to report for Q4 2023 Hyzon Motors Inc. (...
News, Short Squeeze, Breakout and More Instantly...
CRISPR Therapeutics AG Company Name:
CRSP Stock Symbol:
NASDAQ Market:
-Naimish Patel, M.D., appointed to Chief Medical Officer- -Julianne Bruno, M.B.A., promoted to Chief Operating Officer- ZUG, Switzerland and BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transforma...
2024-05-22 09:10:00 ET With a gene therapy for two illnesses out the door, and with sales slated to take off over the next few quarters, CRISPR Therapeutics (NASDAQ: CRSP) is making it a good time to be a shareholder. But could this biotech's halcyon days be so good that a $10,0...